GlaxoSmithKline and Impax Pharmaceuticals entered an agreement for the development and commercialization of IPX066, Impax’s extended release carbidopa-levodopa product, outside the U.S. and Taiwan. IPX066 is an investigational drug under development for the treatment of Parkinson’s Disease (PD), and is currently in Phase III trials. GSK will have an exclusive license to sell IPX066 throughout the world except in the U.S. and Taiwan. Impax will receive $11.5 million upfront and is eligible to ...